A clinical study TO evaluate the efficacy of AYUSH drug on Covid 19 patients

A clinical study on the efficacy of NF1 AND NF3 IN THE TREATMENT OF COVID 19 POSITIVE PATIENTS ALONG WITH STANDARD CARE

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/08/035908

Enrollment

100

Registered

2021-08-25

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: History of fever Cough Willingness to participate in the study Patient should be ready to give written consent Indian Nationals

Exclusion criteria

Exclusion criteria: Age less than 18 years or more than 65 years Pregnancy and Lactation T2DM CVS disorders Renal Problems(CKD) COPD Bronchial Asthma Malignancy CVA

Design outcomes

Primary

Measure	Time frame
RTPCR NEGATIVE Reducing the signs and symptoms and changes in biomarkersTimepoint: Day5 Day10	—

Secondary

Measure	Time frame
trial drug will be more effective than placebo change in biomarkersTimepoint: DAY 1 DAY 5 DAY 10	—

Countries

India

Contacts

Public ContactDr Sanjib Kumar Das

Sri Sri College of Ayurvedic Science and Research Hospital

ayursanjib@gmail.com9437292457

Outcome results